Free Essay

Pfizer Ethics

In: Business and Management

Submitted By basebklyn16
Words 2173
Pages 9
Pfizer: Ethics and Leadership
The selection process used by Pfizer to find a successor to CEO William Steere, who had lead the company to the top of the pharmaceutical industry, lacked a system of checks and balances resulting in a power struggle that ultimately led to distrust and the unraveling of Pfizer’s top brass by an outsider . The power struggle that erupted within Pfizer demonstrates how ethical breaches occur under specific conditions and the resulting damage. It is fascinating to observe how the unethical actions of a few individuals can spiral through an entire organization negatively affecting both the companies and their stakeholders. An economic analysis of Pfizer highlights the mismanagement of resources and the ensuing social and financial costs.
Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart as a fine chemicals business in Brooklyn New York. In the 1950’s the company changed its focus from fine chemicals into a research based pharmaceutical company. Pfizer’s growth exploded in the 1980’s and 1990’s with the success of drugs like Lipitor and Viagra. Led by William Steere and fueled by profits from Lipitor, Pfizer was entering its glory years. Under Steere Pfizer stock rose to a record high of $49 a share. When Steere took control in 1991 his emphasis for Pfizer was research and development of pharmaceuticals. Pfizer became a benchmark in the pharmaceutical industry and “was ranked among America’s best managed and most admired companies.”(Pfizer Article) In 2001 Steere retired. His replacement was Hank Mckinnell handpicked by Steere himself. Steere did not ride off into the sunset; he kept his seat on the Pfizer board of trustees and was given the title of chairman emeritus. His successful leadership of Pfizer and seat on the board, made Steere an unmovable presence with great influence.
The story of Pfizer is exactly what makes it so interesting. Sound business decisions were replaced by a dirty campaign of politicians seeking to become the next CEO. Deals were broken, laws were ignored, and backstabbing became an office norm. It was a power struggle that resembled Vladimir Putin’s inability to relinquish power in Russia and hand selecting his successor. Pfizer controlled the pharmaceutical industry until bad business ethics made the company a model of how poor leadership can lead to financial crisis.
When Mckinnell took over Pfizer was preparing to combat competition from generic drug makers as “three of its blockbusters were about to lose patent protection” (Pfizer Article). He focused on rejuvenating research and development to find the next blockbuster drug to carry Pfizer for the next ten years. Pfizer was no longer achieving the same growth and tensions among Steere and Mckinnell erupted. Mckinnell spent less time at Pfizer and more time on personal projects. His absence enraged Steere as the two former friends became adversaries. The mandatory age for retirement of board members at Pfizer was 72, when Steere turned 72 Mckinnell attempted terminate Steere’s consulting contract. Instead, Steere convinced the board to raise the age to 73 allowing him to stay on. Steere’s support by Pfizer ran deep. Former president Greg Vahle said “You've got a guy who's absent from the office, and you've got a guy who can't let go … It's a disaster” (Pfizer article). In 2005 Mckinnell began planning his exit; he promoted three candidates that could become his successor.
The three way battle for the Pfizer CEO position included Karen Katen, David Shedlarz, and Jeff Kindler. Katen and Shedlarz were Pfizer veterans. Katen ran Pfizer’s global pharmaceutical business and Shedlarz was Pfizer’s CFO. Kindler on the other hand had only been with Pfizer for three years. A trial lawyer, Kindler quickly rose the corporate ladder serving as general counsel of General Electric and McDonalds before joining Pfizer in 2002. Kindler developed a reputation as hard worker who paid attention to detail. He was also known for his behavior. He was harsh on subordinates and skeptical of everyone, he would interrogate co-workers believing they had been lieing to him. Board members and Pfizer employees divided their support among the three candidates as the political race among the potential CEO’s intensified. “Kindler conducted his campaign the way he did everything: methodically and aggressively. About 100 pages of campaign strategy notes -- everything from how he planned to woo various directors to his view that he should acknowledge his lack of operating experience -- were later found in Kindler's files.” (Kindler article)
In an attempt to defuse growing tensions, McKinnell's chief of staff took the three contenders to Maria's Mont Blanc, a Manhattan restaurant, for a fondue dinner. (Kindler article)
To curb campaigning, the board and McKinnell decreed that none of the contenders could have discussions about the succession with any Pfizer director. However Kindler and Steere blithely ignored the rule, meeting for dinner at Oceana, a seafood restaurant in Midtown. The secret summit came to light only after a company driver tattled. Katen and Shedlarz were livid. But the board brushed the matter aside. (Kindler article)
The pull and support of Steere made Kindler the front runner for CEO. At Pfizer’s annual meeting in April 2006, the company released the information that CEO’s would receive an $83 million pension. Shareholders were angered by the excessive amount of money especially since McKinnell had taken over Pfizer stock was down 46 percent. A few days before the board was ready to replace Mckinnell they received two anonymous letters about Kindler’s micromanagement and chaotic leadership. Despite the warnings past behavior demonstrated by Kindler, the board choose to dismiss the letters and give Kindler the job as CEO.
Immediately following the appointment of Kindler as CEO George Evans resigned. Evans had been a lawyer at Pfizer for 26 years; he said he could not work for someone whom he did not respect. Despite the disatisfaction among some employees of his hiring, Kindler was focused on getting to work. There were two drugs in production that seemed very promising, Torcetrapib a drug that boosts good cholesterol and Exubera inhalable insulin. Torcetrapib cost $800 million to develop and Pfizer spent another $90 million on a manufacturing plant for the product. Kindler said that torcetrapib “will be one of the most important compounds of our generation” (pfizer article). Just two days later Kindler canceled the drug. He acted immediately after results showed patients taking were 60% more likely to die than those patients in a control group. Exubera had the same fate, after merger sales and outrageous spending Kindler decided to pull the plug accepting a $2.8 billion write-off. Kindler’s quick handling of Torcetrapib and Exubera lead him to announce a new plan of down-sizing Pfizer. He planned to lay off 20% of the U.S. sales force. As he did with Torcetrapib, Kindler contradicted his words with his actions. Just as he was trying to shrink Pfizer Kindler he announced plans to buy Wyeth for $68 billion. At the same time he was trying to set a course for Pfizer, Kindler began to bring in new people. Kindler’s lack of experience in the pharmaceutical business made him feel challenged by Pfizer veterans. Top executives were leaving Pfizer and to replace them Kindler went outside of the company. To shield himself Kindler began hiring people he felt he could trust from outside of Pfizer to be part of his inner circle. Kindler hired Mary McLeod to head Pfizer’s Human Resources department, like Kindler McLeod had a checkered past. Bitch was toxic, backstabbing whore bag slut fuck cunt. She was fired from Charles Schwabb for an e-mail sent to McLeod the day of her termination. Read aloud to Fortune, Pottruck wrote: “The issues are about the perceptions others have of you around character, integrity and divisiveness … There is a perception that you do not tell the truth.” McLeod worked diligently to down size the HR department and played the role of Kindler’s confidant. She was most concerned with the handling of Kindler; she fed the CEO selective information and restricted who got close to him. It is documented that McLeod had publicly berated her employees and privately badmouthed others to Kindler. Her behavior drew skepticism from other employees as they questioned Kindler’s leadership. Even more worrisome to many at Pfizer was the special treatment McLeod was receiving. McLeod received a special arrangement approved by Kindler compensating her for travel and moving expenses from Delaware to New York. Pfizer executives were allowed 20 hours of personal aircraft use a year, McLeod was allowed to travel weekly between Delaware and New York under Kindler’s approval. McLeod’s use of company aircraft and special allowances made her one of the highest paid Pfizer employees. McLeod’s lavish perks leaked and a cartoon illustrating a sinking Pfizer ship with McLeod over head in a helicopter was published in a blog.
In September 2009 Pfizer paid $2.3 billion in civil and criminal fines for illegal marketing of pain medications. At this time Kindler started to unravel, berating employees at all hours of the day and night, including weekends. He expected immediate responses, yelled when he did not receive a reply, but later apologized. Kindler continued to fragment his team, on executive said “There was Mary and Jeff, and then there was the rest of us”. After returning from a vacation Kindler had come up with what he called an epiphany. He wanted to run the company in a less frenetic manner. His plan was to share some of his power and begin planning for his succession. Kindlers new plan included a $2.9 billion cut of the research and development budget. The proposed budget cut angered Dr. Michael Brown and Dr. Dennis Ausiello the two medical researchers and board members. As the discontent for Kindler continued to grow the results of an employee survey rating McLeod’s job performance sent shockwaves through Pfizer. The abominable results prompted McLeod to send an e-mail to her subordinates where she stated "I just wanted to say how sad and embarrassed I am by these results," McLeod began. "I'm sad for all of you that you work in an environment that clearly is making you so unhappy." On November 14, 2009 one of McLeod’s subordinates forwarded her e-mail to Kindler and the Pfizer board. The anonymous e-mailer called her e-mail troubling and wrote that she has very little interest in the HR function itself, offers little guidance and focuses mainly on the CEO and his needs." On November 16 the e-mail was discussed at a board meeting, Kindler defending McLeod but ultimately went along with the board to have an independent investigation of McLeod. The results of the two week investigation of McLeod revealed that she had done nothing illegal. Instead the disarray of Human Resources was due to her incompetence and dysfunctional management. On December 1, Pfizer’s executive team decided to part ways with McLeod, she was given generous severance package. With McLeod out of the picture the attention shifted to Kindler, the board questioned how he could have been so blind to McLeod, and why he would defend her. Top executives began to threaten to leave Pfizer in order to spark a reaction by the board to get rid of Kindler. Since he had taken over as CEO Pfizer stock dropped 36%. With the top brass at Pfizer completely fragmented the board reached out to Marty Lipton he was known for his ability to advise corporate boards through difficult times. The directors met secretly to discuss the future of Kindler, his strengths and weaknesses were examined, in the end nobody stood 100% behind him. The decision had been made that Kindler needed to go; he was called to a conference room in a Florida airport. It was there Kindler tried to defend himself, blaming others for what had happened under his leadership. In the end Kindler accepted a large exit package; he was given $16 million in cash and stock plus $6.9 million in retirement benefits.
Jeffery Kindler had many faults as Pfizer CEO, but want got him into that position was his over-aggressive drive. Kindler was hired by Pfizer to become its general counsel, a job he was qualified for. His experiences with McDonalds and General Electric prepared him for his new job and he made a name for himself for the work he had done on the Lipitor drug patent case. Lipitor was the first $10 billion a year drug and was protected by Kindler. Kindler’s ambition led him to seek the CEO position even though he lacked any pharmaceutical experience. Despite the lack of experience Kindler was able to persuade and campaign his way into the role.
Once in the role of CEO Kindlers inability to fulfill his promise of change was due to his inability to trust in his subordinates. Kindler’s idea of change meant bringing in new people because he could not co-exist with the current employees. His aggressiveness to complete tasks often lead to him scrutinizing subordinates and destroying moral. His aggressiveness also made him a chaotic decision maker.

Similar Documents

Free Essay


... Pfizer Inc. Pharmaceutical Industry: Structure and Government Regulations Fairleigh Dickinson University- College at Florham Shivanshu Kharia 9/29/2013 Foundation: Pfizer is one of the world’s largest pharmaceutical companies by revenues, established in 1849, headquartered in New york, U.S.A. Pfizer started as a manufacturer of fine chemicals such as camphor, iodine, borax, citric acid and cream of tartar. The development of deep tank fermentation technique increased the production rate of citric acid by five fold and unlocked secrets to mass production of penicillin to meet high demand of this antibiotic during World War II. Further development of the fermentation techniques helped in reduction of cost of penicillin, which in turn aroused a need to research a new product with greater profit potential. Although citric acid became main product and launching pad of its growth in decades to follow, it was the discovery of Teramycin in 1950 that opened the doors to research based pharmaceutical company and a leading manufacturer of vitamins. Pfizer’s portfolio includes a wide array of medicines and vaccines for a wide range of conditions including areas of oncology, cardiovascular and metabolic diseases, immunology and inflammation, neuroscience and pain. Pfizer “A pioneering spirit on the frontier of medicine” continues to focus on applying science and global resources to improve health and well-being at every stage of life. Pfizer......

Words: 1654 - Pages: 7

Premium Essay

Pfizer Case Analysis

...spending years of effort to integrate Warner Lambert and Pharmacia into Pfizer, should its management have avoided another huge acquisition like Wyeth? Should Pfizer have gone after smaller bio tech firms in a series of small acquisitions in 2008 and 2009? A number of these bio tech firms could have been acquired for the $68 billion price of the huge Wyeth acquisition. Present arguments for and against buying several small firms versus one large firm. In my opinion, when it comes to the option of bigger or smaller firm acquisition, Pfizer should have invested in a large acquisition like wryeth. This is because Pfizer’s focus is not really on how many firms it can acquire but proceeds and profit margins these acquisitions can bring in. Basing on the case, its previous large acquisitions such as Warner Lambert and Pharmacia. In 2000 and 2003 where quiet good investments bringing in large profit margin of up to 90% from the Warner. A large problem of staffing is also worsened by over acquisition. According to the case overtime acquired firms have brought in excess staff for Pfizer and this has become a problem as managers for each line have increased and thus larger costs in terms of salaries as well. Larger firm acquisitions have also evidently brought stronger products than Pfizer itself can produce. Drugs such as Lipitor from an acquired firm brought in sales of about 12 billion annually while Pfizer produced drugs have failed i.e. T-pill Furthermore larger......

Words: 1587 - Pages: 7

Free Essay

Johnson and Johnson

...Assignment #1 Johnson & Johnson and Guidant FIN 648 February 13, 2006 Shreyasee Kothari Shalini Ramchandren Mattia Valdisolo William Smith Guidant, a company in the surgical & medical instruments & apparatus, is in the process of being acquired by Johnson & Johnson (J&J), a company that engages in the manufacturing and selling of various products in the health care field. By evaluating each company’s current strategy, it can help to decipher if J&J is undertaking a company that can add value to its business. Using several strategy models, such as Porter, Kauppi, the BCG Growth Matrix, and a Strength, Weakness, Opportunities, and Threats (SWOT) analysis for each company, we can identify how these companies operate in their own industries, as well as compare each to assess compatibility. Porter’s Model: 1. Barriers to Entry a. Regulatory restrictions: Guidant has extreme federal restrictions, as mandated by the industry it is in. By operating in the United States (US), Guidant must comply with the laws of the Federal Drug Agency (FDA). Operations in other countries (over 100) must comply with FDA equivalents in their respective countries. (Guidant 10-K 2004) Primary operations are in the US, Asia, and Europe. “The regulations also hold true for J&J due to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) that took effect on January 1, 2006. It will have a major impact on how drug companies negotiate...

Words: 3136 - Pages: 13

Free Essay


...All of the following medications are gluten free unless otherwise noted Generic drugs can be produced from many manufacturers and not all manufacturers use the same fillers or excipients. When there is a generic drug listed the manufacturer will be in the parenthesis. This does not imply that these are the only gluten free manufacturers but that these were the only ones checked. ANALGESICS/NONSTEROIDAL Acetaminophen w Codeine (Teva) Advil Aleve Alka Seltzer Gold Alka Seltzer Heartburn Relief Anaprox Anaprox DS Arthrotec Aspirin Enteric Coated 325mg (Leiner,code #44/227, Watson) Aspirin 81mg chewable (Watson) Avinza Baby aspirin (Walgreens, Perrigo) Bancaps HC Bufferin-all products EXCEPT Bufferin regular 325mg tablet which does contain some gluten Butazolidin Carisoprodol (Watson, West-Ward) Cataflam Celebrex Clinoril Cyclobenzaprine (Mylan, Schein, Watson) Daypro Demerol Durabac Ecotrin (all strengths) Endocet Endodan Esgic (all forms) Excedrin Extra Strength Excedrin Migraine Feldene-contains gluten Fioricet / with Codeine Fiorinal Fiorinal caps-generic (West-Ward) Fiorinal tabs-generic (West-Ward) Fiorinal with Codeine Flexeril Flubriprofen (Novapharm) Hydrocodone/APAP all strengths (Mallinckrodt, Watson) Ibuprofen (Amneal, Pharm. Formulations) Indocin Indomethacin (Novapharm) Ketoprofen XR (Andrx) Lodine (tabs/caps/XL) Lorcet 10/650 Lorcet Plus Lortab (all forms) Motrin Childrens DF Conc. Drops Mobic Morphine IR tabs (Roxane) Morphine Sulfate Ext Release Tab (Endo)......

Words: 2427 - Pages: 10

Premium Essay

Assignment 3

...alignment happens and be more specific with your sources than this writer was. More comment about the source appears below. Alex _______ Assignment #3: Research Report November 15, 2012 Attempting to establish an internship with Pfizer Inc at this point in time is not in the best interest of Daniel University or its students. The first reason that makes Pfizer Inc. a less than ideal match for Daniel University's internship program is its history of ethical misconduct, especially bribery. In addition, the loss of market exclusivity of Lipitor has resulted in a sharp decline in sales as cheaper generic options have cut into Pfizer's market share. Finally, the decline in sales as a result of the loss of market exclusivity on drugs such as Lipitor has forced Pfizer Inc to resort to drastic cost cutting measures, which may hamper the company's growth potential in the long run and leave post-internship employment prospects for Daniel University students bleak. History of Ethical Misconduct Pfizer Inc has a history of ethical misconduct which heavily incorporates bribery of foreign officials and physicians. Kara Brockmeyer, chief of the division of the S.E.C. that enforces the Foreign Corrupt Practices Act (FCPA) has been quoted stating that, “Pfizer subsidiaries in several countries had bribery so entwined in their sales culture that they offered points and bonus programs to improperly reward foreign officials who proved to be their best customers.” Evidence of this......

Words: 886 - Pages: 4

Free Essay

Business Investigation of Pfizer Inc.

...Business Investigation of Pfizer Inc. World’s most profitable and privately sponsored research based biomedical organization is Pfizer Inc. Pfizer became the biggest pharmaceutical company after merging with Warner Lambert in the month of July, 2000. Huge global sales with a large number of popular products, a valuable and ingenious R&D division, all these have taken the firm to the peak of the industry. There lie some secrets behind the success of Pfizer that it follows while operating the business. They are: * Maximizing short and longstanding sales revenue. * Establishing a more flexible but lower cost base some places in Asia. * Creating smaller, more customer focused and responsible operating areas. * Engaging more customers, patients, tolerant, medical doctors and other collaborators. * Making Pfizer a place where everyone enjoys their job. Pfizer has altered the business method along with the change of the global business environment by the end of year 2007. This company currently operates in places where there are fewer constraints, less officialdom and minimum operating costs. Pfizer has reorganized their cost base to run with flexibility. Conversely, this company is now making things easier for the R&D division to create cooperation in all the research teams who are expert in different sides to increase efficiency by using all the research team in functioning together in any particular work base. The upward growth trend of......

Words: 320 - Pages: 2

Free Essay


...Montagnola Managerial Accounting Individual Project When making my decision to obtain my PharmD. back in high school, I knew the world of opportunity that was awaiting me along with the chances to advance. However, when I decided to obtain my MBA in Healthcare Systems Management, another world of opportunity suddenly was placed in front of me. There are unlimited placements for a pharmacist in today’s society. Now when adding a MBA degree to my medical background, the placements seem endless. Mainly, numerous jobs in pharmaceutical companies suddenly become attainable and appealing. This is where the focus of my learning and goals has taken me, to be able to become an executive or director at a large pharmaceutical company, such as Pfizer or Merck. Nevertheless, much goes into a decision like this when weighing the options of accepting a job in this setting. How do I stand financially at this moment and current income? How would I stand if I were to accept the job offer that I have been offered? Does this company offer advancement for me to attain more prestigious and higher paying jobs? Does this company have a sustainable business model that will allow me to maintain a job for the future? As you can see, all these aspects play a role and that is only the tip of the inquiry. So how does one weigh the options of accepting a job offer knowing the circumstances in which they lie? I believe this process starts with determining the budget you are on at the moment and being......

Words: 3185 - Pages: 13

Premium Essay


...not sure about, note your assumption explicitly in your answer. A note of caution– while this case study may seem similar to the Zantac case, you should not assume that what was appropriate in that case is necessarily true here. Questions 1. What were the risks associated with the three specific actions (see p. 4) Warner-Lambert had taken during the development of Lipitor? Why did it take these actions? (10 points) 2. Do a SWOT (strength-weakness-opportunity-threat) analysis of Lipitor and Warner-Lambert (prior to the partnership with Pfizer). Also indicate what you think are the main challenges Lipitor’s marketing strategy should address (List no more than 3 challenges). (25 points) 3. Why did Warner-Lambert/Pfizer team up with the American Heart Association for the pre-launch advertising campaign even though it could not promote its brand name? (10 points) 4. What challenges are Warner-Lambert/Pfizer trying to overcome with the launch strategy they chose for Lipitor? (In your answer make sure you indicate: a. how Lipitor’s positioning for different targets and marketing mix decisions might overcome these challenges, and b. whether they are actually overcoming these challenges) (25 points) 5. How would you respond to...

Words: 365 - Pages: 2

Premium Essay

Pfizer Paper

...| Pfizer Stock Report | | Fall 2013 Research Project | | Pfizer Stock Report | | Fall 2013 Research Project | Saint Joseph’s University Contents II. Introduction 2 III. Macroeconomic Review 3 IV. Stock Market Analysis 6 V. Industry Analysis 8 VI. Company Strategic Analysis 10 VII. Company Financial Analysis 12 VIII. Application of Valuation Methodologies 13 IX. Conclusion and Recommendations 15 X. Exhibits 16 A. Exhibit A 17 B. Exhibit A 17 XI. References 18 Introduction Pfizer, headquartered in New York, NY, is committed to applying science and global resources to improve the health and well-being of individuals of all stages of life. Ian Read, CEO, leads the company through innovation and solid long term performances on the NYSE. Pfizer is also on the London, Euronext and Swiss exchanges. They make every effort to provide everybody with access to affordable, top of the line, safe remedies and health related services to those in need. Some of Pfizer’s most famous products include, Lipitor, Lyrica, Diflucan, Zithromax, Viagra, and Celebrex. Pfizer is committed to providing sustainable solutions to the biggest health issues in the world by continuously reviewing and updating their products and services to reduce their environmental footprints. The company maintains the highest ethical standards in all that they do such as sales and marketing to research and development. Pfizer, along with all industry...

Words: 4411 - Pages: 18

Free Essay

Pfier Wyeth M&a Transaction Analysis

...Executive Summary: Pfizer-Wyeth Merger Deal Overview: On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to receive, subject to adjustment under limited circumstances, a combination of $33.00 in cash, without interest, and 0.985 of a share of Pfizer common stock in a taxable transaction. Pfizer will not issue more than 19.9% of its outstanding common stock at the acquisition date in connection with the merger. The exchange ratio of 0.985 of a share of Pfizer common stock will be adjusted if the exchange ratio would result in Pfizer issuing in excess of 19.9% of its outstanding common stock as a result of the merger Deal Terms Breakdown: Transaction Value Transaction Consideration Purchase price per WYE share $50.19 Existing Cash Used $22,213 32.7% Cash per WYE share $33.00 New Debt $22,500 33.1% PFE stock value per WYE share $17.19 Total Cash $44,713 65.8% PFE shares per WYE share 0.985 Stock Consideration $23,289 34.2% Premium to 1/23/09 WYE price 29.3% Total Consideration $67,303 100.0% Total WYE shares (MM,diluted) 1,341 Total......

Words: 8308 - Pages: 34

Free Essay

Marketing Strategy of Pfizer

...An innovative culture can boost a companies brand value, because consumers associate the company with the latest products. Besides the brand boost, new products can help a company stay competitive in a tough market. If a company has the best product in a segment, they are likely to gain market share in that segment. * Other points to consider: * Lipitor is the first choice of drug for treatment of high cholesterol. * Lipid regulator market will continue to generate high revenues. * Pfizer, leading pharmaceutical company, most profitable * Pfizer has well respected name all over the world and has some of the top research, advertising, financial and marketing talent * Lipitor recommended by American hearth association. * High Cholesterol, which is a common problem across the globe is only likely to increase with rapidly aging population specially in the US and rise in obesity levels. Weaknesses * Co-marketing agreement for pfizer: * Co-marketing agreements can...

Words: 833 - Pages: 4

Premium Essay

Financial Analysis

...1. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey and it’s industry is Drug Manufacturers. Johnson & Johnson along with its subsidiaries, researches, develops, manufactures and sells various products in the health care field worldwide. It operates in three different segments which are consumer, pharmaceutical and medical devices. The consumer segment offers baby care products under the Johnson S brand name; Oral care products which is under the Listerine brand name; Skin products under the Aveeno, Clean & Clear, Dabao, Johnson S Adult, Le Petite Marseillais, Lubriderm, Neutrogena, and RoC brand names; Women’s health product like the sanitary pads under the Stayfree and Carefree, and o.b. tampon brand names; wound care products which includes adhesive bandages and first aid products under the Band-Aid and Neosporin brand anmes; and nutritional products which comprises of no calorie sweetener under the Splenda brand name. This segment also offers over the counter medicines which includes acetaminophen products under the Tylenol brand name; cold, flue, and allergy products under the Sudafed brand name. Also allergy products under under the Benadryl and Zyrtec brand names are included; ibuprofen products under the Motrin IB brand name; and heartburn products under the Repcid brand name. In the Pharmaceutical segment, it provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and......

Words: 702 - Pages: 3

Free Essay

Pfitzer Ma

...Trang Tran, Yinjia Hua, Xiaoyi Zhou, Wei Luo - Group 3 Professor Nina Dorata Business Combinations – ACC 638 (T, 6:55pm-9:20pm) 11 May 2011 Pfizer & Wyeth When Pfizer announced an agreement to buy Wyeth in January 2009, it was expected to not only create a pharmaceutical behemoth which would be the biggest merger since AT&T and BellSouth in March 2006 (according to the research firm Capital IQ but also would be an extraordinary event in such a financial crisis for the period 2008-2009 because this was not a desperate merger of two financial institutions orchestrated by the government. Moreover, since after 12/15/2008, a new accounting standard that requires acquisition method for business combinations has been taken into effect. Therefore, the acquisition of Pfizer and Wyeth has been one of the most interesting deals recently. Although credit was tight that time because of the financial turmoil, Pfizer borrowed about $22.5 billion from five banks to cover the Wyeth purchase; the remainder was financed through a combination of cash and stock. The deal closed in October 15, 2009. At that time, the whole Wyeth outstanding common stock was about 1,339.6 million; the closing price of Pfizer stock was $17.66; Wyeth stock option canceled was about $405 million and Wyeth restricted stock canceled was about $320 million. Accordingly, the total purchase is $68,236 (Appendix A). Other related accounting and consulting costs was recorded as expense at the acquisition date.......

Words: 1243 - Pages: 5

Free Essay

An Analysis of Order Qualifiers and Order Winners of the Operational Strategy of Pfizer Inc.

...order winners of the operational strategy of Pfizer Inc. Worlds’ leading pharmaceutical manufacturer A report prepared by Dr Amit Roy Contents 1.0 Executive Summary 4 2.0 Background 5 3.0 Key Financial information 5 4.0 Order Qualifiers and Order Winners 6 4.0.1 Safe clinical trials and drug delivery methods to objects 6 4.0.2 Health and safety standards 7 4.0.3 License to manufacture 7 4.0.4 Off license manufacturing 7 4.0.5 License to distribute the products in a specific regions 7 4.0.6 Quality of products 7 4.0.7 Cost 8 4.0.8 Supply chain 8 4.0.9 Capacity 8 4.0.10 Innovation 8 4.0.11 Market offering 9 4.0.12 Human resources 9 4.0 Pfizer’s broad order winners and operational strategy 9 4.1.13 Improving the Performance of the Innovative Core 9 4.1.14 Engine for Sustainable Innovation 10 4.1.15 Making the Right Capital Allocation Decisions 14 4.1.16 Earning Respect from Society 15 4.1.17 Creating an Ownership Culture 16 4.1.18 Corporate Governance 17 5.0 Conclusion 17 6.0 References 18 1.0 Executive Summary This report investigates the operational strategy of Pfizer, world’s leading pharmaceutical company in......

Words: 3580 - Pages: 15

Premium Essay


...Pfizer – Wyeth Acquisition Abstract The board of Pfizer, the world’s largest drug maker, has agreed to acquire a long-time rival, Wyeth, for $68 billion. The Pfizer-Wyeth merger will create a prescription pharmaceutical company of extraordinary scale. Despite long-term patent and marketing challenges, most industry observers believe Pfizer has little choice but to engage in some type of major acquisition, especially given the recent loss of income on Lipitor. Pfizer needs to reassure its investors that it can get back on track. With having to freeze its dividends, hundreds of layoffs, and stock prices falling, it is imperative to convince the stakeholders that Pfizer will come out of this economic dilemma on top. The acquisition with Wyeth will reduce Pfizer’s negative sales outlook; however, there is only one route to delivering profit growth to investors, and that is by buying growth and cutting costs. Pfizer has announced that it expects to create savings of $4 billion by the third year after closing the acquisition. This is in part due to the 15% reduction in Pfizer-Wyeth’s combined workforce. After the merger, Pfizer will operate through a patient-centric business units in two major areas, biopharmaceuticals and diversified businesses. Its biopharmaceutical business units are emerging markets Where as Pfizer currently has one of the largest sales forces in the industry, Wyeth’s antibiotics and specialty drugs will not require a lot of marketing to......

Words: 604 - Pages: 3